| P50 | author | Yaomin Xu | Q90344508 |
| P2093 | author name string | Zhongming Zhao | |
| | Xingyi Guo | |
| P2860 | cites work | A landscape of driver mutations in melanoma | Q24603357 |
| | Melanoma genome sequencing reveals frequent PREX2 mutations | Q24610463 |
| | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 |
| | Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 |
| | Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial | Q27851856 |
| | Integrated genomic analyses of ovarian carcinoma | Q27860518 |
| | Linear models and empirical bayes methods for assessing differential expression in microarray experiments | Q27860758 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | edgeR: a Bioconductor package for differential expression analysis of digital gene expression data | Q27860819 |
| | The epigenomics of cancer | Q28289975 |
| | TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence | Q28477306 |
| | Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma | Q39304634 |
| | Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. | Q39604101 |
| | Cross-talk between aryl hydrocarbon receptor and mitogen-activated protein kinase signaling pathway in liver cancer through c-raf transcriptional regulation | Q39949896 |
| | Evidence for an aryl hydrocarbon receptor-mediated cytochrome p450 autoregulatory pathway | Q40089340 |
| | Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation | Q40380155 |
| | Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas | Q41251515 |
| | Antitumor effects of liposomal IL1? and TNF? against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice | Q54169077 |
| | Poems syndrome with high interleukin (IL)6 and IL1β serum levels, in a patient with thyroid carcinoma and melanoma | Q56967004 |
| | IL-1β Upregulates IL-8 Production in Human Müller Cells Through Activation of the p38 MAPK and ERK1/2 Signaling Pathways | Q63407236 |
| | Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials | Q28730438 |
| | Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma | Q29614282 |
| | Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 |
| | Cancer epigenetics: from mechanism to therapy | Q29614799 |
| | Distinct sets of genetic alterations in melanoma | Q29614965 |
| | COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 |
| | Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 |
| | Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. | Q33352015 |
| | Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1. | Q33581231 |
| | Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays | Q33593399 |
| | A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance | Q33875566 |
| | Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis | Q33946905 |
| | Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. | Q34049618 |
| | The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis | Q34128053 |
| | A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors | Q34132936 |
| | Seminal plasma induces the expression of IL-1α in normal and neoplastic cervical cells via EP2/EGFR/PI3K/AKT pathway | Q34199061 |
| | Directed phenotype switching as an effective antimelanoma strategy. | Q34352683 |
| | Somatic activation of KIT in distinct subtypes of melanoma | Q34569987 |
| | Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation | Q34737289 |
| | Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer | Q35134003 |
| | The INK4a/ARF locus and melanoma | Q35146563 |
| | New Perspectives of "omics" Applications in Melanoma Research | Q35670683 |
| | The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells | Q35801395 |
| | BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration | Q36021702 |
| | Role of transforming growth factor Beta in human cancer | Q36073421 |
| | Epidermal growth factor (EGF) and interleukin (IL)-1β synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion | Q36510571 |
| | Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development | Q36620077 |
| | BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. | Q36692818 |
| | Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma | Q37104104 |
| | The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma | Q37626102 |
| | Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? | Q37775417 |
| | Cancer epigenomics: beyond genomics | Q37991917 |
| | Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. | Q38002668 |
| | Role of aryl hydrocarbon receptor in cancer. | Q38109748 |
| | A melanocyte lineage program confers resistance to MAP kinase pathway inhibition | Q39067618 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | limma | Q112236343 |
| P304 | page(s) | 60 | |
| P577 | publication date | 2015-03-14 | |
| P1433 | published in | Molecular Cancer | Q15724585 |
| P1476 | title | In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma | |
| P478 | volume | 14 | |